What Tiazac Treats: Main Uses and Benefits

Tiazac is a medication primarily used in the management of two major cardiovascular conditions: hypertension (high blood pressure) and chronic stable angina (chest pain).

This medication is used for the treatment of hypertension, to help with lowering blood pressure, and to improve exercise tolerance in patients with chronic stable angina. These uses address conditions characterized by periods of heightened symptoms, which include episodes of chest discomfort and symptoms related to systemic imbalance.

For patients managing these symptoms related to physical discomfort and systemic imbalance, Tiazac contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability. It is often used during phases when symptoms become more noticeable. This is commonly used to help with symptoms that create noticeable physiological strain and may be part of symptomatic management.

Quick Fact: Relief for Symptoms related to physiological strain

The medication may assist with managing symptoms associated with acute or episodic changes, providing supportive relief during episodes of heightened physiological stress.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults being treated for the labeled indications (hypertension or chronic stable angina).

Populations for whom use is not recommended (if applicable):

• Pediatric patients, as safety and effectiveness have not been established [DailyMed].
• Breastfeeding women, due to the drug's excretion into human milk; discontinuing nursing or the drug is advised.
• Pregnant women (EU/UK Labeling), where use is generally contraindicated.

Populations for whom use is contraindicated:

• Patients with Sick Sinus Syndrome or Second- or Third-Degree AV Block, except when a functioning ventricular pacemaker is present.
• Patients with Severe Hypotension (systolic blood pressure below 90 mm Hg), Cardiogenic Shock, or Acute Myocardial Infarction and Pulmonary Congestion.
• Patients with Atrial Fibrillation or Atrial Flutter associated with an accessory bypass tract (e.g., Wolff-Parkinson-White syndrome).
• Patients with known hypersensitivity to diltiazem hydrochloride or any component of the formulation.

Condition-specific eligibility rules:

• Use requires caution in patients with impaired hepatic or renal function due to altered drug clearance.
• Use requires caution in patients with Heart Failure or impaired ventricular function.

Connection to the overall eligibility profile: Regulatory documents define eligibility based on the patient's cardiovascular health and specific physiological states. The labeling establishes absolute contraindications (must not be used) for patients with severe conduction defects or acute cardiac instability. Use is primarily limited to adults, and the label mandates caution for populations with organ impairment or those who are pregnant or breastfeeding, reflecting mandatory eligibility restrictions.

Interactions with other medicines and products

Tiazac’s official interaction profile is characterized by its influence on cardiac conduction and its effect on metabolic pathways. Regulatory documents state that Tiazac is an inhibitor of the CYP3 A4 enzyme, which is responsible for metabolizing many other medicines. This status causes an increase in the systemic exposure of CYP3 A4 substrates, such as the benzodiazepines Midazolam and Triazolam, where exposure is documented to increase by several-fold. Conversely, the herbal product St. John’s Wort, an enzyme inducer, can decrease Tiazac’s plasma concentration.

Formal prohibitions established by regulatory authorities include the contraindication of co-administration with Intravenous Beta-blockers and the mandated avoidance of Ivabradine. For combinations like Ranolazine, a specific maximum dosage restriction is required. Furthermore, co-administration with Cimetidine significantly increases Tiazac’s own plasma levels.

In terms of additive pharmacodynamic effects, combining Tiazac with Oral Beta-blockers or Digitalis may result in cumulative effects on cardiac conduction. The requirement for dosage adjustment of co-administered CYP3 A4 substrates is highlighted as particularly relevant for patients with renal and/or hepatic impairment.

️ How Tiazac Works

The action of Diltiazem (Tiazac) stems from its core function as a non-dihydropyridine calcium channel blocker, which results in two distinct, coordinated physiological changes on the cardiovascular system by inhibiting the influx of calcium ions ( Ca^2+) through L-type Voltage-Gated Calcium Channels ( Cav1.2).

---

Modulating the Heart's Electrical Conduction System

This domain covers the drug's effect on the Sinoatrial (SA) and Atrioventricular (AV) nodes, which establish heart rhythm and conduction speed. By limiting Ca^2+ influx, Diltiazem slows the electrical signal transmission, resulting in Negative Chronotropy (slower heart rate) and Negative Dromotropy (slower conduction velocity), thereby modulating activity within the cardiac electrical conduction pathway.

---

Reducing Arterial Smooth Muscle Tone

This domain addresses the drug's peripheral action on the vascular system, where the same calcium channel is present on arterial smooth muscle cells. By suppressing the Ca^2+ influx required for contraction, the drug promotes vasodilation (vessel widening), which reduces Peripheral Vascular Resistance and consequently reduces the Afterload (the force opposing ventricular ejection).

How to Use Tiazac: Administration Guidelines

This section describes the administration instructions for the use of Diltiazem Hydrochloride Extended-Release Capsules (Tiazac).

---

Dosing and Administration Protocol

Instruction Category	Administration Details
Route of Administration	The medication is intended for oral administration only.
Dosing Schedule	Dosing is typically once daily at approximately the same time each day.
Standard Adult Dose	Initial dosing for adults generally starts between 120 mg and 240 mg once daily. The maximum recommended daily dose for the extended-release formulation is 540 mg.
Titration Interval	Dosage adjustments, or titrations, occur at intervals of 7 to 14 days to allow for the full clinical effect of the dose to be observed.
Physical Handling	The extended-release capsule is swallowed whole and not chewed, crushed, or split to maintain the controlled-release properties.

---

Contextual Use and Special Conditions

Instruction Category	Administration Details
Food Relationship	Can be taken without regard to food (with or without a meal).
Alternative Intake	The capsule contents can be opened and sprinkled onto a spoonful of applesauce and swallowed immediately, without subdivision.
Population-Specific Use	For patients who are elderly or have impaired hepatic or renal function, clinical monitoring and a lower initial dose, such as 120 mg once daily, are utilized.

These instructions collectively form the standardized protocol for the chronic administration of Tiazac. Following the once-daily schedule and maintaining the physical integrity of the capsule are part of the process to ensure the intended extended-release delivery of the active ingredient over a 24-hour period.

Research evidence / Overview of Studies for Tiazac

---

Evidence for Use in Essential Hypertension

Research examining Tiazac was studied for essential hypertension (high blood pressure) using short-term, randomized controlled trials (RCTs). These studies were designed to compare the medicine against a placebo or other active treatments. The primary research examined changes in blood pressure, specifically the systolic and diastolic numbers, over the 24-hour dosing period. Studies monitored outcomes related to BP changes and indicated patterns related to dose-related changes in these measurements. Long-term outcomes, such as patterns related to the risk of stroke or heart attack, are not fully established by trials for this specific formulation but are generally inferred from broader meta-analyses covering the entire pharmacological class.

---

Evidence for Use in Chronic Stable Angina

For chronic stable angina, the research also relies on short-term RCTs. These functional studies were designed to determine how measured exercise time changed in studied populations, focusing on outcomes related to physical discomfort. Researchers monitored outcomes reflecting daily functioning using treadmill tests and tracked episodic changes by counting angina attacks. Studies monitored outcomes related to changes in measured exercise duration. However, follow-up durations for these primary anti-anginal functional studies were typically limited to short or intermediate periods (a few weeks to a few months).

---

Research Limitations and Uncertainties

The research base highlights that while short-term functional measures are structured with RCTs, there is limited information for long-term outcomes regarding the maintenance of symptom control and the patterns of future cardiovascular events. Furthermore, data for certain groups remain insufficient. Studies often excluded individuals with severe heart conditions or significant pre-existing impairment of ventricular function. Consequently, the results apply only to the studied populations, and subgroup findings are uncertain for those with complex coexisting medical conditions.

Key Studies & References

1. Diltiazem Hydrochloride Extended-Release Tablets Prescribing Information (Tiazac/Cardizem/Dilacor XR equivalent monograph)

Common questions about Tiazac (FAQ)

Q: What is Tiazac, and how does it work to treat high blood pressure?

A: Tiazac is a brand name for the drug diltiazem hydrochloride. It belongs to a class of medicines called calcium channel blockers (CCBs).

It is used to treat high blood pressure (hypertension) and angina (chest pain).

Diltiazem works by blocking calcium from entering the muscle cells of the heart and blood vessel walls. This action causes:

• Relaxation and widening of blood vessels, which lowers blood pressure.
• Slowing of the heart rate and a reduction in the heart's workload, which helps relieve angina.

Tiazac is an extended-release capsule, which means the medication is released slowly into the body over a full day, allowing for once-daily dosing.

Q: What are the most common side effects of Tiazac?

A: Like all medications, Tiazac can cause side effects, though not everyone experiences them. The most common side effects are often mild and may improve as your body adjusts to the medication. They can include:

• Headache
• Dizziness or lightheadedness
• Swelling in the ankles, feet, or hands (peripheral edema)
• Nausea
• Fatigue (tiredness)
• Slowed heartbeat (bradycardia)

If you experience any severe or persistent side effects, or signs of an allergic reaction (such as rash, itching, severe dizziness, or trouble breathing), you should contact your doctor immediately.

Q: Can Tiazac be taken with food, and what should I do if I miss a dose?

A: Tiazac extended-release capsules can be taken with or without food.

It is important to swallow the capsules whole. Do not chew, crush, or divide the capsule, as this will destroy the extended-release feature and could lead to a sudden release of too much medicine.

If you miss a dose:

• Take the missed dose as soon as you remember.
• If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule.
• Do not take two doses at the same time to make up for a missed dose.

If you are unsure about what to do after missing a dose, consult your healthcare provider or pharmacist.

Q: Who should not take Tiazac?

A: Tiazac is not suitable for everyone. Certain conditions or medications may make Tiazac unsafe for you. You should not take Tiazac if you have:

• A known allergy to diltiazem or any other ingredients in Tiazac.
• Severe low blood pressure (hypotension).
• Certain serious heart rhythm problems (e.g., Sick Sinus Syndrome or second- or third-degree AV block) unless you have a functioning pacemaker.
• Recent heart attack and a buildup of fluid in the lungs.

It is crucial to inform your doctor about all your current and past medical conditions, especially heart, kidney, or liver problems, and any other medications you are taking, including over-the-counter medicines and supplements.

How to Store and Dispose of Tiazac (Diltiazem Hydrochloride)

Official regulatory documents define specific storage and handling requirements for Tiazac Extended-Release Capsules to maintain product stability and safety.

---

Storage Requirements

• Temperature: Store at Controlled Room Temperature, specified as 25°C (77°F). Temperature excursions are allowed between 15°C and 30°C (59°F and 86°F).
• Protection: The medicine must be protected from excessive humidity and dispensed in a tight, light-resistant container with a child-resistant closure.
• Child Safety: The product must be kept out of the reach of children.
• Post-Administration Stability: If the capsule contents are opened and mixed with applesauce, the mixture must be used immediately and should not be stored for later use.

---

Disposal

Expired or unused Tiazac must be disposed of in accordance with local regulations for pharmaceutical waste, as instructed by regulatory guidance.